1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with n-methylaspartate in 3 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (n-methylaspartate) | Trials (n-methylaspartate) | Recent Studies (post-2010) (n-methylaspartate) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 10,408 | 59 | 1,902 |
| Protein | Taxonomy | 1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50) | n-methylaspartate (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.175 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benavides, J; Gotti, B; MacKenzie, ET; Scatton, B | 1 |
| Barks, JD; Eun, BL; Liu, XH; Silverstein, FS | 1 |
| Dewhurst, S; Gelbard, HA; Maggirwar, SB; Ramirez, S; Tong, N | 1 |
3 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and n-methylaspartate
| Article | Year |
|---|---|
The pharmacotherapy of focal cortical ischaemia in the mouse.
Topics: Animals; Calcium Channel Blockers; Cell Survival; Cyclandelate; Ischemic Attack, Transient; Male; Mice; Molecular Structure; N-Methylaspartate; Piperidines; Platelet Activating Factor; Receptors, GABA-A; Receptors, Opioid; Receptors, sigma; Vincamine | 1990 |
The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Corpus Striatum; Diterpenes; Excitatory Amino Acid Agonists; Fibrinolytic Agents; Functional Laterality; Ginkgolides; Hippocampus; Hypoxia, Brain; Ischemic Attack, Transient; Lactones; N-Methylaspartate; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Time Factors | 1996 |
HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity.
Topics: Animals; Antimanic Agents; Azepines; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Cerebellum; Enzyme Activation; Excitatory Amino Acid Agonists; Gene Products, tat; Glycogen Synthase Kinase 3; Glycogen Synthase Kinases; HIV-1; Lithium Chloride; N-Methylaspartate; Neurons; Neurotoxins; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Recombinant Proteins; tat Gene Products, Human Immunodeficiency Virus; Triazoles | 1999 |